Cargando…

Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study

OBJECTIVE: This study mainly observes the efficacy and safety of almonertinib plus chemotherapy compared with almonertinib alone in the second-line treatment of advanced non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). METHODS: In this study, clinical data of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Xiaoxu, Xiang, Yan, Lu, Kaihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518400/ https://www.ncbi.nlm.nih.gov/pubmed/37752994 http://dx.doi.org/10.3389/fonc.2023.1248690

Ejemplares similares

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

Development and Validation of a UHPLC–MS/MS Method for Quantitation of Almonertinib in Rat Plasma: Application to an in vivo Interaction Study Between Paxlovid and Almonertinib
por: Tang, Peng-fei, et al.
Publicado: (2022)

Case report: Almonertinib in combination with bevacizumab for leptomeningeal metastases from epidermal growth factor receptor-mutation non-small cell lung cancer: Case series
por: Zhang, Yuhai, et al.
Publicado: (2022)

Almonertinib-induced interstitial lung disease: A case report
por: Jiang, Ting, et al.
Publicado: (2021)

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation
por: Hou, Zhiwei, et al.
Publicado: (2023)

Absorption, metabolism, excretion, and safety of [(14)C]almonertinib in healthy Chinese subjects
por: Zhou, Chen, et al.
Publicado: (2021)

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report
por: Pan, Hai, et al.
Publicado: (2023)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
por: Liu, Yaming, et al.
Publicado: (2021)

Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
por: Zhou, Qian, et al.
Publicado: (2023)

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study
por: ZHU, Lucheng, et al.
Publicado: (2021)

Almonertinib as a neoadjuvant therapy for patients with a superior pulmonary sulcus tumor with activated EGFR mutation: A case report
por: Kang, Kai, et al.
Publicado: (2023)

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
por: Shen, Gang, et al.
Publicado: (2021)

Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR
por: Almalki, Faisal A., et al.
Publicado: (2021)

Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
por: Zhang, Yuhan, et al.
Publicado: (2021)

Case report: sequential use of almonertinib based on the EGFR exon 20 insertion mutation achieves long-term control for advanced non-small cell lung cancer patients
por: Wang, Ruilin, et al.
Publicado: (2022)

Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review
por: Chen, Wenyan, et al.
Publicado: (2022)

Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review
por: Wu, Longqiu, et al.
Publicado: (2021)

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
por: Chen, Ting, et al.
Publicado: (2022)

Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified
por: Chen, Zegeng, et al.
Publicado: (2021)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Surgery Plus Chemotherapy Versus Surgery Alone for Limited-Stage Small-Cell Lung Cancer: A Population-Based Survival Outcome Analysis
por: Ye, Pingting, et al.
Publicado: (2021)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
por: Li, Lingling, et al.
Publicado: (2020)

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wu, Qiang, et al.
Publicado: (2021)

Best Supportive Care Versus Whole-Brain Irradiation, Chemotherapy Alone, or WBRT Plus Chemotherapy in Patients With Brain Metastases From Small-Cell Lung Cancer: A Case-Controlled Analysis
por: Li, Hongwei, et al.
Publicado: (2021)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer
por: Fang, Xiaoxu, et al.
Publicado: (2022)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
por: Wang, Hao, et al.
Publicado: (2022)

The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
por: Kim, Hye Ryeon, et al.
Publicado: (2021)

PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series
por: Tan, Sirui, et al.
Publicado: (2022)

Radiotherapy Plus Chemotherapy Is Associated With Improved Survival Compared to Radiotherapy Alone in Patients With Primary Vaginal Carcinoma: A Retrospective SEER Study
por: Zhou, Wei-li, et al.
Publicado: (2020)

A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer
por: Wang, Hai-ying, et al.
Publicado: (2020)

The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study
por: Zhou, Zhongbao, et al.
Publicado: (2021)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

Oligorecurrence Non–small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography–Guided (125)I Seed Implantation vs. Second-Line Chemotherapy
por: Wang, Hao, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non–Small Cell Lung Cancer: A Reconstruction of Partitioned Survival Model Based on Time Dependent Pricing Mechanism of Patient Assistance Program
por: Cai, Yuanyi, et al.
Publicado: (2021)

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis
por: Chen, Fei, et al.
Publicado: (2020)

Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
por: Zhu, Jian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_94abiip2pu9i3f73198rks8ikv